Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non-Hodgkin Lymphoma.
| Title: | Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non-Hodgkin Lymphoma. |
|---|---|
| Authors: | Lu D; Genentech Inc., South San Francisco, California, USA.; Lu T; Genentech Inc., South San Francisco, California, USA.; Gibiansky L; QuantPharm LLC, North Potomac, Maryland, USA.; Li X; Genentech Inc., South San Francisco, California, USA.; Li C; Genentech Inc., South San Francisco, California, USA.; Agarwal P; Genentech Inc., South San Francisco, California, USA.; Shemesh CS; Genentech Inc., South San Francisco, California, USA.; Shi R; Genentech Inc., South San Francisco, California, USA.; Dere RC; Genentech Inc., South San Francisco, California, USA.; Hirata J; Genentech Inc., South San Francisco, California, USA.; Miles D; Genentech Inc., South San Francisco, California, USA.; Chanu P; Genentech/Roche, Lyon, France.; Girish S; Genentech Inc., South San Francisco, California, USA.; Jin JY; Genentech Inc., South San Francisco, California, USA. |
| Source: | CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2020 Jan; Vol. 9 (1), pp. 48-59. Date of Electronic Publication: 2019 Dec 23. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Language: | English |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2163-8306 (Electronic) Linking ISSN: 21638306 NLM ISO Abbreviation: CPT Pharmacometrics Syst Pharmacol Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2015- : Hoboken, NJ : Wiley; Original Publication: New York, NY : Nature Pub. Group |
| MeSH Terms: | Models, Biological*; Antibodies, Monoclonal/*pharmacokinetics ; Immunoconjugates/*pharmacokinetics ; Lymphoma, Non-Hodgkin/*drug therapy; Antibodies, Monoclonal/administration & dosage ; Immunoconjugates/administration & dosage ; Clinical Trials as Topic ; Humans ; Linear Models ; Time Factors |
| Abstract: | A two-analyte integrated population pharmacokinetic (PK) model that simultaneously describes concentrations of antibody-conjugated monomethyl auristatin E (acMMAE) and unconjugated MMAE following repeated administrations of polatuzumab vedotin (pola) was developed based on data from four clinical studies of pola in patients with non-Hodgkin lymphoma. A two-compartment model with a nonspecific, time-dependent linear clearance, a linear time-dependent exponentially declining clearance, and a Michaelis-Menten clearance provided a good fit of the acMMAE plasma PK profiles. All three acMMAE elimination pathways contributed to the input to the central compartment of unconjugated MMAE, which was also described by a two-compartment model. Population PK parameters, covariate effects, and interindividual variability of model parameters were estimated. The impact of clinically relevant covariates on PK exposures of each analyte were quantified and reported to support key label claims.; (© 2019 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics.) |
| References: | Blood. 2009 Sep 24;114(13):2721-9. (PMID: 19633198); AAPS J. 2009 Jun;11(2):371-80. (PMID: 19452283); Pharm Res. 2006 Sep;23(9):2036-49. (PMID: 16906454); Semin Cancer Biol. 2013 Dec;23(6):410-21. (PMID: 24060900); Bioanalysis. 2013 Jan;5(2):201-26. (PMID: 23330562); J Pharmacokinet Pharmacodyn. 2006 Jun;33(3):345-67. (PMID: 16284919); AAPS J. 2011 Jun;13(2):143-51. (PMID: 21302010); Nat Biotechnol. 2012 Jan 22;30(2):184-9. (PMID: 22267010); Clin Pharmacokinet. 2012 Feb 1;51(2):119-35. (PMID: 22257150); Bioanalysis. 2013 May;5(9):997-1006. (PMID: 23641692); J Clin Pharmacol. 2017 Sep;57(9):1148-1158. (PMID: 28513851); J Clin Oncol. 2010 Oct 10;28(29):4507-12. (PMID: 20837947); J Clin Pharmacol. 2013 Aug;53(8):866-77. (PMID: 23754575); J Pharmacokinet Pharmacodyn. 2001 Oct;28(5):481-504. (PMID: 11768292); CPT Pharmacometrics Syst Pharmacol. 2016 Dec;5(12):665-673. (PMID: 27863168); CPT Pharmacometrics Syst Pharmacol. 2017 Jun;6(6):401-408. (PMID: 28544534); J Pharmacokinet Pharmacodyn. 2017 Dec;44(6):537-548. (PMID: 28918591); CPT Pharmacometrics Syst Pharmacol. 2014 Oct 29;3:e144. (PMID: 25353187); Lancet Oncol. 2015 Jun;16(6):704-15. (PMID: 25925619); Int J Mol Sci. 2016 Apr 14;17(4):561. (PMID: 27089329); Nat Biotechnol. 2003 Jul;21(7):778-84. (PMID: 12778055); Lancet Oncol. 2019 Jul;20(7):998-1010. (PMID: 31101489); Br J Clin Pharmacol. 2017 Aug;83(8):1782-1790. (PMID: 28239897); Lancet Haematol. 2019 May;6(5):e254-e265. (PMID: 30935953) |
| Substance Nomenclature: | 0 (Antibodies, Monoclonal); 0 (Immunoconjugates); KG6VO684Z6 (polatuzumab vedotin) |
| Entry Date(s): | Date Created: 20191122 Date Completed: 20210616 Latest Revision: 20210616 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC6966185 |
| DOI: | 10.1002/psp4.12482 |
| PMID: | 31749251 |
| Database: | MEDLINE |
Journal Article; Research Support, Non-U.S. Gov't